Search Results for "Axitinib Pharmacokinetic"
Original Source: Pharmacokinetic evaluation of axitinib.
Introduction: The role of angiogenic inhibitors is clearly established in the treatment of diverse malignancies. The field of antiangiogenesis is expanding rapidly, with an increasing number of agents currently approved by the FDA. Axitinib is a vascular endothelial growth factor receptor (VEGFR)-specific inhibitor currently being developed for the treatment of various malignancies. The pharmacokinetic (PK) properties of axitinib may provide a selective treatment effect while minimizing adverse reactions...
Matching Channels
Generics Drugs - news, views, reports
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration,...
Matching News
EU approves Pfizer's axitinib and Takeda/NPS's teduglutide
The EMA has approved new drugs from Pfizer (axitinib) and Takeda/ NPS Pharmaceuticals (teduglutide) following their endorsement by the CHMP at its May and June meetings respectively. Pfizer's axiti...
Axitinib Granted Marketing Approval in Europe
The European Commission has approved the use of axitinib in adult patients with renal cell carcinoma who have failed prior therapy. International Approvals
Pfizer’s Axitinib receives positive opinion from the CHMP
The CHMP of the EMA has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU)...
Although overall survival, a secondary endpoint for the study, did not differ between the two groups, investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group....
Pfizer receives EU Marketing Authorization for INLYTA®(Axitinib)
The European Commission has granted marketing authorization for INLYTA® (axitinib)...
NICE Consults on Preliminary Recommendations for a New Kidney Cancer Drug
NICE, the healthcare guidance body, has issued draft guidance not recommending axitinib (Inlyta, Pfizer) for the treatment of advanced kidney cancer. The preliminary decision by the independent Appra...
NEW YORK--(BUSINESS WIRE)--Oct 17, 2012 - Pfizer Inc. announced today that a Phase 3 study of INLYTA® (axitinib) did not meet its primary endpoint of demonstrating statistically significantly long...
NEW YORK--(BUSINESS WIRE)--Oct 17, 2012 - Pfizer Inc. announced today that a Phase 3 study of INLYTA® (axitinib) did not meet its primary endpoint of demonstrating statistically significantly long...
Matching PubMed Articles
PURPOSE: Axitinib, an orally administered inhibitor of vascular endothelial growth factor 1, 2 and 3, is primarily metabolized by cytochrome P450 (CYP) 3A4/5 but is also a substr...
Purpose Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3, is under investigation for treatment of various solid tumors....
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
Objective Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor co...
Pharmacokinetic evaluation of axitinib.
Introduction: The role of angiogenic inhibitors is clearly established in the treatment of diverse malignancies. The field of antiangiogenesis is expanding rapidly, with an increasing number of agent...
Clinical Pharmacology of Axitinib.
Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 that is approved in the US and several other countries for treatment of patie...
